Last reviewed · How we verify
CRTE7A2-01 TCR-T Cell
At a glance
| Generic name | CRTE7A2-01 TCR-T Cell |
|---|---|
| Sponsor | Corregene Biotechnology Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers (PHASE1)
- CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRTE7A2-01 TCR-T Cell CI brief — competitive landscape report
- CRTE7A2-01 TCR-T Cell updates RSS · CI watch RSS
- Corregene Biotechnology Co., Ltd portfolio CI